Marinus: Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
Read full article »
Marinus is a Pennsylvania-based biopharmaceutical company that develops and commercializes therapies for the treatment of epilepsy and neuropsychiatric disorders.
Read more